Cardioprotective effect of ellagic acid on doxorubicin induced cardiotoxicity in wistar rats

Background/AimThe objective of the study was to evaluate the cardioprotective activity of ellagic acid in doxorubicin induced cardiotoxicity.MethodsMale wistar rats (180–220 g) were divided in to four groups: vehicle control, doxorubicin control, ellagic acid (100 mg/kg) and ellagic acid (200 mg/kg). Doxorubicin was administered to all the groups except vehicle control at a dose of 3.75 mg/kg at week 2,3,4,5 to make a cumulative dose of 3.75 mg/kg. Ellagic acid was administered to the respective group of animals at a dose of 100 mg/kg 200 mg/kg, respectively once daily orally for 6 weeks. On the last day of the study, blood was collected by retro-orbital puncture and LDH and CK-MB were estimated. The animals were cannulated and the ECG and hemodynamic parameters were recorded. The animals were then sacrificed and histology of heart was performed.ResultsDoxorubicin showed cardiotoxicity manifested by changes in serum marker enzymes, ECG and hemodynamic parameters which was further confirmed by histology of heart. This doxorubicin induced changes were attenuated by treatment with ellagic acid (200 mg/kg).ConclusionIt has been concluded that ellagic acid (200 mg/kg) treatment for 6 weeks protects the heart of rats in doxorubicin induced cardiotoxicity.